Impact of prospectively evaluated risk factors in neuroblastoma. Results from the Austrian A-NB87 study;WERTIGKEIT PROGNOSTISCHER FAKTOREN IN DER OSTERREICHISCHEN A-NB87 NEUROBLASTOM STUDIE

Klinische Padiatrie

Volumn 208, Issue 4, 1996, Pages 210-220

  Ladenstein, Ruth ^a   Ambros, Peter F ^a   Urban, Christian ^b   Ambros, Inge M ^a   Fink, Franz M ^c   Zoubek, Andreas ^a   Grienberger, Heinz ^d   Schmitt, Klaus ^e   Kerbl, Reinhold ^b   Horcher, Ernst ^f   Amann, Gabriele ^g   Höfler, Gerhard ^h   Heinzl, Harald ^g   Gadner, Helmut ^a   Mutz, Ingomar ⁱ  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b Universitatsklinik fur Kinder und Jugendheilkunde Graz   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d Salzburger Landeskliniken   (Austria)

^e KEPLER UNIVERSITY HOSPITAL   (Austria)

^f Universitätskinderklinik Wien   (Austria)

^g UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF GRAZ   (Austria)

ⁱ Landeskrankenhaus Leoben   (Austria)

Author keywords

Neuroblastoma; Prospective study; Risk factors

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FERRITIN; IFOSFAMIDE; TENIPOSIDE; VINCRISTINE;

ADOLESCENT; AGE; ARTICLE; AUSTRIA; CANCER STAGING; CHEMOTHERAPY; CHILD; CLASSIFICATION; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEWBORN; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL; UNIVARIATE ANALYSIS;

EID: 8944244055     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1046476     Document Type: Article

References (53)

1. Kinnier Wilsosn, L. M., G. J. Draper: Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br. Med. J. 3 (1974) 301
2. Berthold, F., W. E. Brandeis, F. Lampert: Neuroblastoma:diagnostic advances and therapeutic results in 370 patients. In Monogr. Paediatr. 18 (1986) 206-223
3. Zucker, J. M., E. Margulis: Radiochemotherapy of postoperativ minimal residual disease in neuroblastoma. Recent results. Cancer Res. 68 (1978) 423-430
4. Evans, A. E., G. J. D'Angio, C. E. Koop: The role of multimodal therapy in patients with local and regional neuroblastoma. J. Ped. Surg. 19 (1984) 77-82
5. Ninane, J., F. X. Wese: Treatment of localized neuroblastoma. Am. J. Ped. Hematol./Oncol. 8 (1986) 248-252
6. De Benardi, B., D. Rogers, M. Carli et al.: Localized neuroblastoma, surgical and pathological staging. Cancer 60 (1987) 1066-1072
7. Nitschke, R., E. I. Smitz, S. Shochat, G. Altshule, H. Travers, J. J. Shuster, F. A. Hayes, K. Patterson, N. McWilliams: Localized neuroblastoma treated by surgery: A Pediatric Oncology Group Study. J. Clin. Oncol. 6 (1988) 1271-1279
8. Matthay, K. K., H. N. Sather, R. C. Seeger et al.: Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J. Clin. Oncol. 7 (1989) 236-244
9. Nitschke, R., E. I. Smith, G. Altshuler et al.: Postoperative treatment of non metastatic visible residual neuroblastoma: A Pediatric Oncology Group Study. J. Clin. Oncol. 9 (1991) 1181-1188
10. Castleberry, R. P., L. E. Kun, J. J. Shuster et al.: Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group Stage C neuroblastoma. J. Clin. Oncol. 9 (1991) 789-795
11. Kushner, B. H., M. P. La Quaglia, P. F. Amros et al.: Survival from locally invasive or metastatic neuroblastoma without cytotoxic therapy. ASCO 29th meeting, Orlando 16-18 Mai 1993. Proc. Am. Soc. Clin. Oncol. 12 (1993) 414 (Abstr. 1417)
12. Garaventa, A., B. De Benardi, C. Pianca et al.: Localized but resectable neuroblastoma: Treatment and outcome of 145 cases. J. Clin. Oncol. 11 (1993) 1770-1779
13. De Benardi, B., M. T. Di Tullio, L. Cordero di Montezelmo et al.: Neuroblastoma under one year of age. In: Lampert, F., L. Cordero di Montezelmo, A. Pession (eds.): Contributions to Oncology. Cancer in the first year of life. Basel, Karger, pp 118-128,1990
14. Adams, G. A., S. J. Shochat, E. I. Smith et al.: Thoracic neuroblastoma: A Pediatric Oncology Group study. J. Ped. Surg. 3 (1993) 372-378
15. Ninane, J., J. Pritchard, P. H. M. Jones et al.: Stage II neuroblastoma. Adverse prognostic significance of lymphnode involvement. Arch. Dis. Child. 57 (1982) 438-442
16. Rosen, E. M., J. R. Cassady, C. Kretschmer et al.: Influence of local-regional lymph node metastases on prognosis in neuroblastoma. Med. Pediatr. Oncol. 12 (1984) 260-263
17. Philip, T., J. M. Zucker, J. L. Bernard et al.: Improved survival at 2 and 5 years in the LMCE1. An unselected group of 72 children with stage iv neuroblastoma oldet than 1 year of age at diagnosis. Is cure possible in a small subgroup? J. Clin. Oncol. 9 (1991) 1037-1044
18. De Benardi, B., M. Carli, F. Casale et al.: Standard dose and high-dose peptichemio and cisplatin in children with disseminated poor risk neuroblastoma: Two studies by the Italian Cooperative Group for Neuroblastoma. J. Clin. Oncol. 10 (1992) 1870-1878
19. 19' Kushner, B. H., L. Helson: Coordinate use of sequentially escalated cyclophosphamid and cell-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: Experience with 100 patients. J. Clin. Oncol. 5 (1987) 1746-1750
20. Berthold, F., Ch. Bender-Götze, R. Dopfer, R. Erttmann, R. J. Haas, G. Henze, M. Körbling, H. Riehm, M. Rister, B. Stollmann, D. Niethammer: Myeloablative Chemo- und Radiotherapie mit autologer allogener Knochenmarksrekonstitution bei Kindern mit metastasierendem Neuroblastom. Klin. Päd. 200 (1988) 221
21. Pearson, A. D. J., A. W. Craft, C. R. Pimkerton et al.: High-dose rapid schedule of chemotherapy for disseminated neuroblastoma. European Journal of Cancer 28A (1992) 1654-1659
22. Dini, G., E. Lamino, A. Garaventa et al.: Myeloablativ therapy and unpurged autologous bone marrow transplantation for poor prognosis neuroblastoma: Report of 34 cases. J. Clin. Oncol. 9 (1991) 962-969
23. Gordon, S. J., A. D. J. Pearson, M. M. Reid, A. W. Craft: Toxicity of single-day high-dose vincristine, melphalan, etoposid and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma. European Journal of Cancer 28A (1992) 1319-1323
24. Corbett, R., R. Pinkerton, Pritchard et al.: Pilot study of high-dose vincristine, etoposid, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma. European Journal of Cancer 28A (1992) 1324-1328
25. Graham-Pole, G.: Advanced neuroblastoma: A Pediatric Oncology Group Study. J. Clin. Oncol. 9 (1991) 152-158
26. Hartmann, O., E. Benhamour, F. Beaujean et al.: Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J. Clin. Oncol. 5 (1987) 1205-1211
27. Kushner, B. H., R. J. O'Reilly, L. R. Mandell et al.: Myeloablativ combination chemotherapy without total body irradiation for neuroblastoma. J. Clin. Oncol. 9 (1991) 274-279
28. Ludenstein, R., O. Hartmann, C. R. Pinkerton: The role of megatherapy with autologous bone marrow rescue in solid tumors of childhood. Annals of Oncology 4 (Suppl. 1) (1993) 45-58
29. Hartmann, O., E. Benhamour, F. Beaujean et al.: Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J. Clin. Oncol. 5 (1987) 1205-1211
30. Dehner, L. P.: Classic neuroblastoma: Histopathologic grading as a prognostic indicator. The Shimada system and its progenitors. Amer. J. Ped. Hemat./Oncol. 10 (1988) 143-154
31. Evans, A. E., G. J. D'Angio, K. Propert, J. Anderson, H. L. Hann: Prognostic factors in neuroblastoma. Cancer 59 (1987) 1853
32. Ladenstein, R., C. Lasset, O. Hartmann et al.: High-dose Consolidation Chemotherapy in infants with stage 4 neuroblastoma. Eur. J. Cancer. Vol. 29A, No. 11, 1632, 1993
33. Ladenstein, R., C. Urban, H. Gadner, F. M. Fink, A. Zoubek: First exerience with prognostic factors in unselected neuroblastoma patients. The Austrian neuroblastoma 87 study. Eur. J. Cancer. Vol 31A, 637-641, 1995
34. Brodeur, G. M., C. Azar, M. Brother, J. Hiemstra, B. Kaufmann, H. Marshall, J. Molley, A. Nakagawara, R. Saylors, N. Scavarda, S. Schneider, J. Wasson, P. White, R. Seeger, T. Look, R. Castleberry: Neuroblastoma. Effect of genetics on prognosis and treatment. Cancer 70 (1992) 1685-1694
35. Caron, H., P. van Sluis, J. de Kraker et al.: Allelil loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl. Jour. Med., Vol 334, No. 4, 225-230, 1996
36. Christiansen, H., S. Fuchs, N. M. Christiansen et al.: Loss of the pitative tumor suppressor gene locus 1p36 as investigated by a PCR assay and N-Myc amplification in 48 neuroblastomas: results of the German Neuroblastoma Study Group. Sixth Symp. Adv. Neurobl. Res. Philadelphia 13-15 Mai 1993
37. Ambros, P. F., I. M. Ambros, R. Ladenstein, H. Gadner: Neuroblastoma: Impact of biological characteristics on treatment strategies. Onkologie 18 (1995) 548-555
38. Ambros, P. F., I. M. Ambros, S. Strehl, S. Bauer, A. Luegmayer, H. Kovar, R. Ladenstein, F. M. Fink, E. Horcher, G. Printz, I. Mutz, F. Schilling, C. Urban, H. Gadner: Regression and progression in Neuroblastoma. Does genetics predict tumour behaviour? Eur. J. Cancer 31A (1995) 510-515
39. Evans, A. E., G. J. D'Angio, J. R. Randolph: A proposed staging for children with neuroblastoma: A report from the Children's Cancer Study Group. Cancer 27 (1971) 374
40. Kaplan, E. L., Meier: Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53 (1958) 457-481
41. Mantel, N.: Cancer Chemotherapy Reports 50 (1966) 163-170
42. Cox, D. R.: Regression models and life tables. Journal of the Royal Statistical Society B, 34 (1972) 187-220
43. Mutz, I., Ch. Urban, H. Gadner, O. A. Jürgenssen, A. Zoubek: Ergebnisse der Neuroblastombehandlung in Österreich (1979-1984). Pädiatrie und Pädologie 21 (1986) 269
44. Cheung, N.-K. V., G. Heller: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J. Clin. Oncol. 9 (1991) 1050-1058
45. McCowage, G., M. R. Vowels, P. J. Shaw, L. Lockwood, H. Mameghan: Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation. J. Clin. Oncol. 13 (1995) 2789-2795
46. Brodeur, G. M., C. T. Fonc: Molecular biology and genetics of human neuroblastoma. Cancer Genet. Cytogenet. 41 (1989) 153-174
47. Seeger, R. C., G. M. Brodeur, Sather et al.: Association of multiple copies of the N-myc Oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313 (1985) 1111-1116
48. Delattre, O., M. Peter, J. Michon et al.: Simultaneous detection of Ip allelic loss and N-myc oncogene amplification at diagnosis in neuroblastoma. SIOP XXIIIrd. meeting. Rhodes 1-4 Oct., 1991, Abstr. 30
49. Look, A. T., F. A. Hayes, J. J. Shuster et al.: Clinical relevance of tumor cell ploidy and NMyc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group Study. J. Clin. Oncol. 9 (1991) 581-591
50. Zeltzer, P. M., P. J. Marangos, A. E. Evans, S. L. Schneider: Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 57 (1986) 1230
51. Hann, H. L., A. E. Evans, S. E. Siegel et al.: Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: the Children's cancer Study Group experience. Cancer research 45 (1985) 2843-2848
52. Berthold, F., R. Trechow, S. Utsch, J. Zieschang: Prognostic factors in metastatic neuroblastoma. American Journal of pediatric Haematology/Oncology 14 (1992) 207-215
53. Berthold, F., R. Kassenböhmer, J. Zieschang: Multivariate evaluation of prognostic factors in localized neuroblastoma. Am. J. Pediatr. Hematol. Oncol. 2 (1994) 107-115